Molecular techniques and prostate cancer diagnostic

European Urology

Volumn 44, Issue 4, 2003, Pages 390-400

  Montironi, Rodolfo ^a   Mazzucchelli, Roberta ^a   Scarpelli, Marina ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Comparative genomic hybridization; DNA array; Fluorescence in situ hybridization; Laser capture microscopy; Prostate cancer; Reverse transcription polymerase chain reaction; Tissue microarray

Indexed keywords

CANCER DIAGNOSIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOMICS; LASER MICROSCOPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEOMICS; QUANTITATIVE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SLICE;

EID: 0141595009     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00309-9     Document Type: Review

References (81)

1. Montironi R. Prognostic factors in prostate cancer. Br Med J 2001;322:378-9.
2. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet 2001;27:172-80.
3. Bova GS, Partin AW, Isaacs SD, Carter BS, Beaty TL, Isaacs WB, et al. Biological aggressiveness of hereditary prostate cancer: long-term evaluation following radical prostatectomy. J Urol 1998;160:660-3.
4. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
5. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
6. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 2002;32:581-3.
7. Chen H, Griffin AR, WU YQ, Tomsho LP, Zuhlke KA, Lange EM, et al. RNASEL mutations in hereditary prostate cancer. J Med Genet 2003;40:e21.
8. Conlon EM, Goode EL, Gibbs M, Standford JL, Badzioch M, Janer Kolb S, et al. Ologenic segregation analysis of hereditary prostate cancer pedigrees: evidence for multiple loci affecting age at onset. Int J Cancer 2003;105:630-5.
9. Karan D, Lin MF, Johansson SL, Batra SK. Current status of the molecular genetics of human prostatic adenocarcinoma. Int J Cancer 2003;113:285-93.
10. Li C, Gronberg H, Matsuyama H, Weber G, Nordenskjold M, Naito K, et al. Difference between wedish and Japanese men in the association between AR CAG repeats and prostate cancer suggesting a susceptibility-modifying locus overlapping the androgen receptor gene. Int J Mol Med 2003;11:529-33.
11. Valdman A, Nordenskjold A, Fang X, Naito A, Al-Shukri S, Larsson C, et al. Mutation analysis of the BRG 1 gene in prostate cancer clinic samples. Int J Oncol 2003;22:1003-7.
12. Verhage BA, van Houwelingen K, Ruijter TE, Kiemeney LA, Schalken JA. Allelic imbalance in hereditary and sporadic prostate cancer. Prostate 2003;54:50-7.
13. Wiklund F, Jonsson BA, Goransson I, Bergh A, Gronberg H. Linkage analysis of prostate cancer susceptibility: confirmation of linkage at 8p22-23. Hum Genet 2003;112:414-8.
14. Chen C, Hyytinen ER, Sun X, Helin HJ, Koivisto PA, Frierson HF, et al. Delection, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003;162:1349-54.
15. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 1997;3:2269-74.
16. He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS, et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
17. Heidenberg HB, Sesterhenn IA, Gaddipati JP, Weghorst CM, Buzard GS, Moul JW, et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995;154:414-21.
18. Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Wang Y, Hayward SW, et al. NKX3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res 2002;62:2999-3004.
19. Kwabi-Addo B, Giri D, Schmidt K, Podsypanina K, Parsons R, Greenberg N, et al. Haploinsufficiency of the PTEN tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-8.
20. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
21. Otto T, Rembrink K, Goepel M, Meyer-Schwickerath M, Rubben H, E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma. Urol Res 1993;21:359-62.
22. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
23. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
24. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57:4455-9.
25. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1998;95:15587-91.
26. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998;159:941-5.
27. Waters JJ, Barlow AL, Gould CP. FISH. J Clin Path: Mol Pathol 1998;51:62-70.
28. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 2002;12:67-86.
29. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-62.
30. Skacel M, Ormsby AH, Pettay JD, Tsiftsakis EK, Liou LS, Klein EA, et al. Aneusomy of chromosomes 7, 8 and 17 and amplification of HER-2/neu and Epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray. Hum Pathol 2001;32:1392-7.
31. Takahashi S, Quian J, Brown JA, Alcaraz A, Bostwick D, Lieber MM, et al. Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994;54:3574-9.
32. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Ande KL, et al. Loss of p53 and c-myc over-representation in stage T(2-3) N(I-3) M(0) prostate cancer are potential markers for cancer progression. Mod Pathol 2002;15:35-44.
33. Weiss MM, Hermsen MAJA, Meijer GA, van Grieken NCT, Baak JPA, Kuipers EJ, et al. Comparative genomic hybridization. J Clin Pathol: Mol Pathol 1999;52:243-51.
34. Roylance R. Methods of molecular analysis: assessing losses and gains in tumours. J Clin Pathol: Mol Pathol 2002;55:25-8.
35. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du MS, et al. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995;14:267-76.
36. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
37. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
38. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, et al. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
39. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, et al. Chromosomal changes during development and progression of prostate adenocarcinoma. Br J Cancer 2001;84:202-8.
40. O'Connor SL, Hee Cho J, McDonnell TJ. The application of molecular techniques to solid tumors. Sem Diagn Pathol 2002;19:94-103.
41. Ghossein RA, Bhattacharya S. Molecular detection and characterization of circulating tumour cells and micro-metastases in solid tumours. Eur J Cancer 2000;36:1681-94.
42. Gewanter RM, Katz AE, Olsson CA, Benson MC, Singh A, Schiff PB, et al. RT-PCR for PSA as a prognostic factor for patients with clinically localized prostate cancer treated with radiotherapy. Urology 2003;61:967-71.
43. Gelmini S, Tricarico C, Petrone L, Forti G, Amorosi A, Dedola GL, et al. Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med 2003;41:261-5.
44. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996;273:1516-7.
45. Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, et al. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998;58:4497-504.
46. Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000;60:6111-5.
47. Lin X, Tascilar M, Lee WH, Vles WJ, Lee BH, Veeraswamy R, et al. GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol 2001;159:1815-26.
48. Millar EK, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinico-pathological study of 16 cases. Histopathology 1996;29:11-9.
49. Baak JPA, Path FRC, Hermsen MAJA, Meijer G, Schmidt J, Janssen EAM. Genomics and proteomics in cancer. Eur J Cancer 2003;39:1199-215.
50. Lash AE, Tolstoshev CM, Wagner L, Schuler GD, Strausberg RL, Riggins GJ, et al. SAGEmap: a public gene expression resource. Genome Res 2000;7:1051-60.
51. Velculescu VE. Essay: Amersham Pharmacia Biotech & Science prize. Tantalizing transcriptomes-SAGE and its use in global expression analysis. Science 1999;286:1491-2.
52. Waghray A, Schober M, Feroze F, Yao F, Virgin J, Chen YQ. Identification of differentially expressed genes by serial analysis of gene expression in human prostate cancer. Cancer Res 2001;61:4283-6.
53. Long-Cheng L, Hong Z, Hiroaki S, Kane CJ, Dahiya R. PGDB: a curated and integrated database of genes related to the prostate. Nucl Acid Res 2003;31:291-3.
54. Gabrielson E, Berg K, Anbahagan R. Functional genomics, gene array, and the future of pathology. Mod Pathol 2001;14:1294-9.
55. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, et al. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 2003;22:1247-52.
56. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
57. Ferdinandusse S, Denis S, IJlst L, Dacremont G, Waterham HR, Wanders RJ. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000;41:1890-6.
58. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
59. Luo J, Duggan DJ, Chen Y, Sauvageot J, Ewing CM, Bittner ML, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
60. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002;62:2220-6.
61. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61:5692-6.
62. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
63. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
64. Nelson PS. Identifying immunotherapeutic targets for prostate carcinoma through the analysis of gene expression profiles. Ann N Y Acad Sci 2002;975:232-46.
65. Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001;25:1397-404.
66. Kotti TJ, Savolainen K, Helander HM, Yagi A, Novikov DK, Kalkkinen N, et al. In mouse alpha-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. J Biol Chem 2000;275:20887-95.
67. Curran S, McKay JA, McLeod HL, Murray GI. Laser capture microscopy. J Clin Pathol: Mol Pathol 2000;53:64-8.
68. Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001;294:2563-6.
69. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. Alfa-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
70. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
71. Martin DB, Nelson PS. From genetics to proteomic: techniques and applications in cancer research. Trends Cell Biology 2001;11:560-5.
72. Wright Jr GL, Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, et al. Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixture. Prostate Cancer Prostatic Dis 1999;2:264-76.
73. Meehan KL, Holland JW, Dawkins HJ. Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 2002;50:54-63.
74. Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue Microarray strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312-9.
75. Yong EL, Lim J, Qi W, Ong V, Mifsud A. Molecular basis of androgen receptor diseases. Ann Med 2000;32:15-22.
76. Mahmoudi T, Verrijzer CP. Chromatin silencing and activation by Polycomb and trithorax group proteins. Oncogene 2001;20:3055-66.
77. Varambally S, Dhanasekaran SM, Barette TR. EZH2, a Polycomb Group Protein Involved in the Lethal Progression of Prostate Cancer. Nature 2002;419:624-9.
78. Donald CD, Sun CQ, Lim SD, Macoska J, Cohen C, Amin MB, et al. Cancer-specific loss of beta-defensin 1 in renal and prostatic carcinomas. Lab Invest 2003;83:501-5.
79. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47.
80. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
81. Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001;98:9754-9.